Short interest for Twist Bioscience gives investors a sense of the degree to which investors are betting on the decline of Twist Bioscience's stock. Short interest data is updated every two weeks.

Twist Bioscience Stock (NASDAQ:TWST), Short Interest Report

Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Cathie Wood chart2

Equities

News

Markets

ETFs

$BTC

ARKF

ARKK

ARKW

AVAV

COIN

DKNG

GLBE

RDDT

RKLB

SHOP

STNE

TWLO

TWOU

TWST

On Wednesday, Cathie Wood’s Ark Invest made some significant trades.

Cathie Wood&#39;s Ark Invest Purchases Over $30M of Shopify Shares Amid Q1 Numbers-Driven Plunge; Adds Reddit Shares To Kitty — Offloads Coinbase Stock As Bitcoin Declines

Ark Invest CEO Cathie Wood

ARKQ

ARKX

DDOG

PLTR

On Tuesday, the Cathie Wood-led Ark Invest made some significant trades.

Cathie Wood&#39;s Ark Invest Swoops In To Buy The Palantir Dip — Purchases Stock Worth $29M — Offloads Coinbase Shares Worth Over $15M Amid Softening Bitcoin Price

Medicine,Doctor,Touching,Electronic,Medical,Record,On,Tablet.,Dna.,Digital

Analyst Color

Earnings

Guidance

Health Care

Price Target

Reiteration

Analyst Ratings

Movers

Trading Ideas

General

Twist Bioscience reports strong Q2 earnings, with sales up 25% YoY to $75.3M and orders increasing by 45%. Gross margin expands to 41%. Fiscal year guidance was raised, and William Blair sees continued growth momentum. Analysts reaffirm Outperform ratings.

Genomics firm Twist Bioscience&#39;s Momentum To Continue Throughout 2024, Analyst Says

Twist Bioscience Corporation - Common Stock

Twist Bioscience Corp

AVPT

AvePoint Expects Q2 Total Revenues Of $73.8M-$75.8M, Est $75.406M

<p>TimkenSteel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTUS#NYSE">MTUS</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.37 by 51.35 percent. This is a 27.27 percent increase over earnings of $0.44 per share from the same period last year.  The company reported quarterly sales of $321.600 million which beat the analyst consensus estimate of $319.800 million by 0.56 percent.  This is a 0.59 percent decrease over sales of $323.500 million the same period last year.</p>


Earnings Beats

MTUS

TimkenSteel Q1 2024 Adj EPS $0.56 Beats $0.37 Estimate, Sales $321.600M Beat $319.800M Estimate

<p>Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(0.81) by 59.26 percent. This is a 53.93 percent increase over losses of $(2.80) per share from the same period last year.  The company reported quarterly sales of $9.048 million which missed the analyst consensus estimate of $9.104 million by 0.61 percent.  This is a 19.57 percent decrease over sales of $11.249 million the same period last year.</p>


Earnings Misses

LFLY

Leafly Holdings Q1 2024 GAAP EPS $(1.29) Misses $(0.81) Estimate, Sales $9.048M Miss $9.104M Estimate

<p>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 69.44 percent decrease over losses of $(0.36) per share from the same period last year.  The company reported quarterly sales of $14.000 thousand which missed the analyst consensus estimate of $30.000 thousand by 53.33 percent.  This is a 63.16 percent decrease over sales of $38.000 thousand the same period last year.</p>


INMB

INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate

<p>The company is raising its full year&nbsp;outlook&nbsp;for total ARR, total revenues and non-GAAP operating income.</p>


AvePoint Raises FY24 Total Revenue Forecast From $308.6M-$316.6M To $314.3M-$320.3M, Est $314.446M

<p>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.71 percent.</p>


Cue Biopharma Q1 2024 Adj EPS $(0.25) Beats $(0.28) Estimate

<p><strong>--</strong><em><strong> Experienced Leader, Brings Proven Track Record Building Global Consumer Brands --</strong></em></p>
<p>Funko, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>), a leading pop culture lifestyle brand, today announced that its Board of Directors has appointed Cynthia Williams as its Chief Executive Officer (CEO), effective May 20, 2024. Williams is also expected to join the Funko Board of Directors on that date. Michael Lunsford will remain the company&#39;s Interim CEO until Ms. Williams joins the company in May.</p>


Management

FNKO

Funko Appoints Cynthia Williams CEO And Board Member, Effective May 20, 2024

<p>Utilities rarely steal the spotlight in market headlines, often overshadowed by the exponential growth of tech giants and the emergence of<a href="https://www.benzinga.com/topic/artificial-intelligence"> artificial intelligence leaders</a>.</p>
<p>Despite the lack of attention, the utilities sector, represented by the <strong>Utilities Select Sector SPDR Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>), has quietly achieved its seventh consecutive session in the green on Thursday, surpassing the performance of every other sector in the S&amp;P 500 since<a href="https://www.benzinga.com/news/large-cap/24/05/38598252/shocker-of-2024-utilities-overtake-tech-sector-10-stocks-behind-the-shift"> the beginning of the year.</a></p>
<p>With a year-to-date performance of approximately 13.6%, utilities are edging ahead of energy, tracked by the <strong>Energy Select Sector SPDR Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), and doubling the returns of the technology sector, represented by the <strong>Technology Select Sector SPDR Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>).</p>
<h3 class="wp-block-heading">Chart: Utilities Outperform Every S&amp;P 500 Sector Year-To-Date </h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160930/image-56-1024x495.png" alt="" class="wp-image-331371" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160930/image-56-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160930/image-56-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160930/image-56-768x372.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160930/image-56-1536x743.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160930/image-56.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>The true rally of utilities seems to have started less than a month ago. Since April 17, this sector has recorded 15 out of 17 sessions in the green, indicating a significant shift in investor sentiment.</p>
<h3 class="wp-block-heading">Chart: Utilities Rise By 14% Since Mid-April</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160605/image-55-1024x495.png" alt="" class="wp-image-331368" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160605/image-55-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160605/image-55-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160605/image-55-768x372.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160605/image-55-1536x743.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09160605/image-55.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<h3 class="wp-block-heading">Utilities Regain Power, Expert Says</h3>
<p> &#8220;Investors are starting to kick the tires on the sector as a potential derivative play to the AI boom,&#8221; <strong>Adam Turnquist</strong>, chief technical strategist for LPL Financial, wrote in a note.</p>
<p>According to the International Energy Agency (IEA), global electricity demand from data centers could soar to between 650-1,000 terawatt-hours (TWh) by 2026, up from 460 TWh in 2022.</p>
<p>The expert highlighted that surging power demand among data centers could provide a major tailwind for the utilities sector. </p>
<p>Also read:<em><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38497224/ai-data-centers-drive-electricity-demand-goldman-sachs-picks-16-stocks-to-play-the-"> AI Data Centers Drive Electricity Demand: Goldman Sachs Picks 16 Stocks To Play The Trend</a></em></p>
<p>The focus on data centers has also dominated recent earnings calls. For instance, <strong>Dominion Energy Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) powers Northern Virginia, home to the largest data center market globally, where approximately 70% of global internet traffic passes through.</p>
<p>On its May 2 earnings call, Dominion highlighted a significant uptick in data center demand, noting changes in the scale and speed of requests.</p>
<p>Looking at technicals, Turnquist highlighted that the S&amp;P 500 Utilities Sector vs. S&amp;P 500 ratio chart, which tracks trend direction and strength, recently reversed its own downtrend and moved above its 200-day moving average for the first time in over a year. This suggests potential for further outperformance by the utility sector.</p>
<h3 class="wp-block-heading">Chart: Relative Performance Of Utilities Against S&amp;P 500 Surges Above 200-Day Average</h3>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09161818/image-57-1024x495.png" alt="" class="wp-image-331380" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09161818/image-57-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09161818/image-57-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09161818/image-57-768x372.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09161818/image-57-1536x743.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/09161818/image-57.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>Read now: <em><a href="https://www.benzinga.com/markets/equities/24/05/38738050/investors-flock-to-lower-cost-vanguard-s-p-500-etf-is-it-time-to-switch-from-spy-to-voo">Investors Flock To Lower-Cost Vanguard S&amp;P 500 ETF: Is It Time To Switch From SPY To VOO?</a></em></p>
<p><em>Photo via Shutterstock.</em></p>


Large Cap

Long Ideas

Sector ETFs

Broad U.S. Equity ETFs

Technicals

Econ #s

Tech

Utilities Notch 7th Straight Session Of Gains: 'Potential Derivative Play To The AI Boom'

<p>System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.51) by 11.76 percent. This is a 21.62 percent decrease over losses of $(0.37) per share from the same period last year.  The company reported quarterly sales of $84.917 million which beat the analyst consensus estimate of $83.372 million by 1.85 percent.  This is a 49.41 percent decrease over sales of $167.854 million the same period last year.</p>


System1 Q1 2024 Adj EPS $(0.45) Beats $(0.51) Estimate, Sales $84.917M Beat $83.372M Estimate

<p>Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of $(2.52) by 29.37 percent. This is a 83.61 percent increase over losses of $(10.86) per share from the same period last year.  The company reported quarterly sales of $1.255 million which beat the analyst consensus estimate of $1.194 million by 5.15 percent.  This is a 1.87 percent increase over sales of $1.232 million the same period last year.</p>


RKDA

Arcadia Biosciences Q1 2024 GAAP EPS $(1.78) Beats $(2.52) Estimate, Sales $1.255M Beat $1.194M Estimate

Bloom Energy Reaffirms 2024 Outlook, Sees Revenue $1.4B-$1.6B vs $1.49B Est.

<p>Expensify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. This is a 20 percent decrease over earnings of $0.05 per share from the same period last year.  The company reported quarterly sales of $33.535 million which missed the analyst consensus estimate of $35.525 million by 5.60 percent.  This is a 16.37 percent decrease over sales of $40.101 million the same period last year.</p>


EXFY

Expensify Q1 2024 Adj EPS $0.04 Misses $0.05 Estimate, Sales $33.535M Miss $35.525M Estimate

<p>Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.11) by 54.55 percent.  The company reported quarterly sales of $235.300 million which missed the analyst consensus estimate of $250.207 million by 5.96 percent.  This is a 14.50 percent decrease over sales of $275.191 million the same period last year.</p>


Bloom Energy Q1 2024 Adj EPS $(0.17) Misses $(0.11) Estimate, Sales $235.300M Miss $250.207M Estimate

<p>MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.52) by 9.87 percent.  The company reported quarterly sales of $5.890 million which beat the analyst consensus estimate of $37.500 thousand by 15.61K percent.  This is a 0.07 percent decrease over sales of $5.894 million the same period last year.</p>


MEIP

MEI Pharma Q3 2024 Adj EPS $(1.37) Beats $(1.52) Estimate, Sales $5.890M Beat $37.500K Estimate

<p>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.44) by 84.09 percent. This is a 65.31 percent decrease over losses of $(0.49) per share from the same period last year.</p>


ALLK

Allakos Q1 2024 GAAP EPS $(0.81) Misses $(0.44) Estimate

<p>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.94) by 34.04 percent.</p>


VSTM

Verastem Q1 2024 GAAP EPS $(1.26) Misses $(0.94) Estimate

<p><i>AlTi continues to execute strategy to expand scale and reach of its global ultra-high-net-worth ("UHNW") wealth management business in existing and new markets.</i></p>
<p>AlTi Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) ("AlTi" or the "Company"), a leading independent global wealth manager with over $70 billion in combined assets, announces the acquisition of Envoi, LLC ("Envoi"), a leading family office focused on multi-generational family wealth with assets under management (AUM) of approximately $3.0 billion.</p>
<p>This follows AlTi's recent acquisition of US-based independent advisory firm East End Advisors, as AlTi accelerates its strategy to become the leading global independent wealth management platform for the UHNW segment, with targeted expertise in alternatives.</p>
<p>In line with this strategic goal, AlTi is using funding of up to $450 million from Allianz X and Constellation Wealth Capital to fund its mergers and acquisitions pipeline and organic growth activities.</p>


ALTI

AlTi Tiedemann Global Announces Acquisition Of Midwest Family Office, Envoi; Financial Terms Not Disclosed

<p>Chuy's Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.36 by 16.67 percent. This is a 10.64 percent decrease over earnings of $0.47 per share from the same period last year.  The company reported quarterly sales of $110.464 million which missed the analyst consensus estimate of $111.670 million by 1.08 percent.  This is a 1.81 percent decrease over sales of $112.498 million the same period last year.</p>


CHUY

Chuy's Holdings Q1 2024 Adj EPS $0.42 Beats $0.36 Estimate, Sales $110.464M Miss $111.670M Estimate

WIIM

CMBM

Cambium Networks shares are trading lower after the company reported worse-than-expected Q1 financial results.

<p>Spyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(1.17) by 2.56 percent.</p>


SYRE

Spyre Therapeutics Q1 2024 GAAP EPS $(1.20) Misses $(1.17) Estimate

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><a href="https://investorplace.com/industries/healthcare/biotech/">Biotech stocks</a> offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine. But not all biotech companies are the same. Some are established pharmaceutical giants while others are pre-revenue startups that are banking on a drug breakthrough.&nbsp;</p>



<p>What this means is that an FDA approval or denial can have major consequences on the stock. If you want to invest in biotech stocks, you will need to keep up with the company&rsquo;s clinical trial progress as well as study other offerings by the competition. Here are our top three choices for biotech stocks with blockbuster drug pipelines that could pay off massively in the future.&nbsp;</p>



<h2><strong>Moderna (MRNA)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/04/mrna1600-300x169.png" alt="Moderna logo is seen at the entrance to its headquarters in Cambridge, Massachusetts. Moderna, Inc., (MRNA) is an American pharmaceutical and biotechnology company."><div>Source: Tada Images / Shutterstock.com</div></div><p><strong>Moderna </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mrna-stock-quote/"><strong>MRNA</strong></a>) is an American pharmaceutical company based in Massachusetts. This company is best known for its mRNA vaccine for the novel coronavirus which catapulted the stock to the mainstream. MRNA is down by nearly 20% over the past year but Wall Street analysts still see about 25% upside with an average one-year <a href="https://finance.yahoo.com/quote/MRNA/analysis">price target</a> of $132.36.&nbsp;</p>



<p>As its name suggests, Moderna focuses primarily on RNA and mRNA vaccines. Its current pipeline shows how vast the scope of Moderna&rsquo;s research is. Moderna is currently developing treatments for the endemic stage of COVID-19, RSV, influenza and various oncology treatments. As of 2023, Moderna had more than 45 different treatments at the clinical or pre-clinical trial stages.&nbsp;</p>



<p>Revenue has dipped for Moderna since the windfall of the COVID-19 vaccine. Still, the company has a 10-year <a href="https://www.alphaspread.com/security/nasdaq/mrna/financials/income-statement/revenue">revenue</a> CAGR of 43%. Shares are trading at 6.1x sales which is higher than in recent years for mRNA but lower than the average P/S ratio of the <a href="https://www.alphaspread.com/security/nasdaq/mrna/relative-valuation">biotech industry</a> which sits at about 8.1x sales.&nbsp;</p>



<h2><strong>Twist Biosciences (TWST)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/11/twst1600-300x169.png" alt="Scientific handling a light microscope examines a laboratory sample for pharmaceutical bioscience research. Concept of science, laboratory and study of diseases. Twist Biosciences (TWST)"><div>Source: dhvstockphoto / Shutterstock.com</div></div><p><strong>Twist Biosciences </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/twst-stock-quote/"><strong>TWST</strong></a>) is a San Francisco-based biotech company that specializes in DNA and synthetic DNA treatments. Shares of TWST are down by about 9.0% in 2024 but Wall Street analysts remain optimistic. They have an average one-year <a href="https://finance.yahoo.com/quote/TWST/analysis">price target</a> of $40.25 which represents about 30% upside from its current price.&nbsp;</p>



<p>This biotech company has a unique business strategy that has allowed it to stand apart from its competition. Twist can write up to one million DNA sequences directly onto a silicon chip which is used by drug makers for research and development. The technology is unique and is highly supported by Cathie Wood.&nbsp;</p>



<p>Incredibly, TWST has increased <a href="https://www.alphaspread.com/security/nasdaq/twst/financials/income-statement/revenue">revenue</a> for 26 consecutive quarters and has a 5-year CAGR of 52%. Shares are trading at a very reasonable <a href="https://finance.yahoo.com/quote/TWST/key-statistics">6.8x sales</a>. Like Moderna, this is below the industry average of 8.1x sales. Twist has a unique technology and clearly business is booming. If you&rsquo;re bullish on biotechs and genomics, TWST is a nice play on the technology side of drug pipelines.&nbsp;</p>



<h2><strong>Axsome Therapeutics (AXSM)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/axsm-stock-300x169.jpg" alt="A magnifying glass zooms in on the Axsome Therapeutics, Inc. (AXSM) logo"><div>Source: Pavel Kapysh/Shutterstock.com</div></div><p><strong>Axsome Therapeutics </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/axsm-stock-quote/"><strong>AXSM</strong></a>) is an American biotech firm that was founded in 2012. Shares of AXSM have lost about 7.0% in 2024 but analysts remain upbeat on the stock with an average <a href="https://finance.yahoo.com/quote/AXSM/analysis">price target</a> of $123.00. This represents nearly 75% upside and this jumps to about 175% when you compare it to the street-high price target for AXSM of $190.00.</p>



<p>This company has a budding pipeline of treatments for a wide range of diseases. Axsome currently has five treatments that are in the clinical or pre-clinical stages of research for diseases such as migraines, Alzheimer&rsquo;s, smoking cessation and fibromyalgia. As you might be able to tell, Axsome focuses primarily on Central Nervous System (<span>CNS</span>) diseases which have minimal or limited current treatments.</p>



<p><a href="https://www.alphaspread.com/security/nasdaq/axsm/financials/income-statement/revenue">Quarterly revenue</a> for Axsome has exploded from $8.8 million in June 2022 to $270 million in the quarter ending December 2023. Due to this, Axsome&rsquo;s <a href="https://finance.yahoo.com/quote/AXSM/key-statistics">P/S ratio</a> has fallen from 50.12x sales in 2023 to 12x sales for the current quarter. This biotech company continues to exhibit massive growth with its strategy of targeting diseases with minimal drug competition.&nbsp;</p>



<p><em>On the date of publication, Ian Hartana and Vayun Chugh did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a></em>.</p>
<div><p>Chandler Capital is the work of Ian Hartana and Vayun Chugh. 

Ian Hartana and Vayun Chugh are both self-taught investors whose work has been featured in Seeking Alpha. Their research primarily revolves around GARP stocks with a long-term investment perspective encompassing diverse sectors such as technology, energy, and healthcare.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/3-biotech-stocks-with-blockbuster-drug-pipelines-april-edition/">3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition

Analyst Catherine Ramsey Schulte from Robert W. Baird maintained a Buy rating on Twist Bioscience (TWST – Research Report) and keeping the price ta...

Twist Bioscience: Strong Demand and Strategic Positioning Fuel Buy Rating

Twist Bioscience GAAP EPS of -$0.79, revenue of $75.3M

Twist Bioscience up 8% on 2024 revenue guidance raise, Q2 beats

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Twist Bioscience</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/twst-stock-quote/"><strong>TWST</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Twist Bioscience reported earnings per share of -79 cents. This was above the analyst estimate for EPS of -81 cents.</li><li>The company reported revenue of $75.30 million.</li><li>This was 6.58% better than the analyst estimate for revenue of $70.65 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/twst-stock-earnings-twist-bioscience-for-q2-of-2024/">TWST Stock Earnings: Twist Bioscience Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TWST Stock Earnings: Twist Bioscience Beats EPS, Beats Revenue for Q2 2024

Twist Bioscience Corporation (TWST) Q2 2024 Earnings Call Transcript

AEON Biopharma, Allarity Therapeutics, ModivCare among healthcare movers

Twist Bioscience: NGS Is Taking Off

In a report released on May 3, Rachel Vatnsdal from J.P. Morgan maintained a Sell rating on Twist Bioscience (TWST – Research Report), with a price...

Twist Bioscience: A Sell Rating Amid Concerns Over Order Sustainability and Premium Valuation

Scotiabank analyst Sung Ji Nam maintained a Buy rating on Twist Bioscience (TWST – Research Report) today and set a price target of $48.00. The com...

Twist Bioscience (TWST) Gets a Buy from Scotiabank

AEON

ALHC

ALLR

AXSM

CRDF

HCTI

MODV

MRNA

TNDM

Press Releases

Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT

Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications

Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience to Present at Upcoming Investor Conferences

Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing

Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024

Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results

Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Twist Bioscience Stock (NASDAQ:TWST), Short Interest Report

People Also Watch